XML 45 R30.htm IDEA: XBRL DOCUMENT v3.25.1
INTANGIBLE ASSETS (Tables)
 3 Months Ended
Mar. 31, 2025
Intangible Assets Disclosure [Abstract]  
Summary of Finite-Lived Intangible Assets
The following table summarizes our Intangible assets, net:
 March 31, 2025December 31, 2024
(in millions)Gross 
Carrying
Amount		Accumulated
Amortization		Foreign Currency Translation AdjustmentNet
Carrying Amount		Gross 
Carrying
Amount		Accumulated
Amortization		Foreign Currency Translation AdjustmentNet
Carrying Amount
Finite-lived assets:
Intangible asset – sofosbuvir$10,720 $(7,923)$— $2,797 $10,720 $(7,749)$— $2,971 
Intangible asset – axicabtagene ciloleucel
7,110 (2,822)— 4,288 7,110 (2,721)— 4,389 
Intangible asset – Trodelvy
11,730 (3,353)— 8,377 11,730 (3,083)— 8,647 
Intangible asset – Hepcludex
845 (351)— 494 845 (329)— 516 
Other1,479 (971)1 510 1,474 (940)1 535 
Total finite-lived assets31,884 (15,421)1 16,465 31,879 (14,822)1 17,058 
Indefinite-lived assets – IPR&D(1)
2,890 — — 2,890 2,890 — — 2,890 
Total intangible assets$34,774 $(15,421)$1 $19,355 $34,769 $(14,822)$1 $19,948 
_______________________________
(1)    The Indefinite-lived assets – IPR&D balance as of March 31, 2025 was comprised of $1.8 billion related to sacituzumab govitecan-hziy (“SG”) for non-small cell lung cancer (“NSCLC”) and $1.1 billion related to bulevirtide.
Summary of Indefinite-Lived Intangible Assets
The following table summarizes our Intangible assets, net:
 March 31, 2025December 31, 2024
(in millions)Gross 
Carrying
Amount		Accumulated
Amortization		Foreign Currency Translation AdjustmentNet
Carrying Amount		Gross 
Carrying
Amount		Accumulated
Amortization		Foreign Currency Translation AdjustmentNet
Carrying Amount
Finite-lived assets:
Intangible asset – sofosbuvir$10,720 $(7,923)$— $2,797 $10,720 $(7,749)$— $2,971 
Intangible asset – axicabtagene ciloleucel
7,110 (2,822)— 4,288 7,110 (2,721)— 4,389 
Intangible asset – Trodelvy
11,730 (3,353)— 8,377 11,730 (3,083)— 8,647 
Intangible asset – Hepcludex
845 (351)— 494 845 (329)— 516 
Other1,479 (971)1 510 1,474 (940)1 535 
Total finite-lived assets31,884 (15,421)1 16,465 31,879 (14,822)1 17,058 
Indefinite-lived assets – IPR&D(1)
2,890 — — 2,890 2,890 — — 2,890 
Total intangible assets$34,774 $(15,421)$1 $19,355 $34,769 $(14,822)$1 $19,948 
_______________________________
(1)    The Indefinite-lived assets – IPR&D balance as of March 31, 2025 was comprised of $1.8 billion related to sacituzumab govitecan-hziy (“SG”) for non-small cell lung cancer (“NSCLC”) and $1.1 billion related to bulevirtide.